JPWO2019138219A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019138219A5 JPWO2019138219A5 JP2020537574A JP2020537574A JPWO2019138219A5 JP WO2019138219 A5 JPWO2019138219 A5 JP WO2019138219A5 JP 2020537574 A JP2020537574 A JP 2020537574A JP 2020537574 A JP2020537574 A JP 2020537574A JP WO2019138219 A5 JPWO2019138219 A5 JP WO2019138219A5
- Authority
- JP
- Japan
- Prior art keywords
- patent document
- disease
- endothelium
- international publication
- international
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000010099 disease Diseases 0.000 description 4
- 210000004204 Blood Vessels Anatomy 0.000 description 3
- 210000003038 Endothelium Anatomy 0.000 description 3
- 206010012601 Diabetes mellitus Diseases 0.000 description 2
- 210000002889 Endothelial Cells Anatomy 0.000 description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 description 2
- 208000009576 Hypercholesterolemia Diseases 0.000 description 2
- 206010034636 Peripheral vascular disease Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- 208000009863 Chronic Kidney Failure Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin resistance Diseases 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- 206010062585 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 206010038444 Renal failure chronic Diseases 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 201000010238 heart disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
Description
内皮細胞および脈管構造の変化は、広範囲のヒト疾患の病因において中心的な役割を果たす。（より包括的なレビューについては、「血管内皮と人間の病気」Ｉｎｔ．Ｊ．ｏｆ Ｂｉｏ．Ｓｃｉｅｎｃｅｓ、２０１３；９（１０）：１０５７－１０６９参照）内皮細胞の層で構成される内皮は、血管の内面であり、バリア機能、血液凝固、炎症、新しい血管の形成、血管収縮および血管拡張などの血管系の重要な側面に関与する。内皮は、末梢血管疾患、脳卒中、心臓病、糖尿病、インスリン抵抗性、慢性腎不全、腫瘍増殖、転移、静脈血栓症、および重度のウイルス感染症に直接関与する。したがって、血管内皮の機能障害は人間の疾患の特徴であり、内皮機能不全は、（これらに限定されないが、）高血糖および糖尿病（Ｉ型およびＩＩ型）および循環器疾患、脳卒中を含む、肺高血圧症、末梢血管疾患、動脈硬化症、および高コレステロール血症を含む多くの臨床疾患のある患者によく見られる。
この出願の発明に関連する先行技術文献情報としては、以下のものがある（国際出願日以降国際段階で引用された文献及び他国に国内移行した際に引用された文献を含む）。
（先行技術文献）
（特許文献）
（特許文献１） 国際公開第２０１８／０８９９０９号
（特許文献２） 国際公開第２００８／１２７８１３号
（特許文献３） 国際公開第０２／４３７４６号
（非特許文献）
（非特許文献１） ＺＨＯＵ ＸＩＡＮＧ ＥＴ ＡＬ，"Ｒｉｂｏｓｏｍａｌ ｐｒｏｔｅｉｎｓ： ｆｕｎｃｔｉｏｎｓ ｂｅｙｏｎｄ ｔｈｅ ｒｉｂｏｓｏｍｅ"， ＪＯＵＲＮＡＬ ＯＦ ＭＯＬＥＣＵＬＡＲ ＣＥＬＬ ＢＩＯＬＯＧＹ， Ｖｏｌ． ７， Ｎｏ． ２， Ａｐｒｉｌ ２０１５ （２０１５－０４）， ｐａｇｅ ９２－１０４
Changes in endothelial cells and vasculature play a central role in the pathogenesis of a wide range of human diseases. (For a more comprehensive review, see "Endothelium and Human Diseases," Int. J. of Bio. Sciences, 2013; 9 (10): 1057-1069.) The endothelium, which is composed of layers of endothelial cells, is a blood vessel. It is the inner surface of the blood vessels and is involved in important aspects of the vascular system such as barrier function, blood coagulation, inflammation, formation of new blood vessels, vasoconstriction and dilation. The endothelium is directly involved in peripheral vascular disease, stroke, heart disease, diabetes, insulin resistance, chronic renal failure, tumor growth, metastasis, venous thrombosis, and severe viral infections. Thus, vascular endothelial dysfunction is a hallmark of human disease, and endothelial dysfunction includes (but is not limited to) hypercholesterolemia and diabetes (types I and II) and cardiovascular disease, stroke. It is common in patients with many clinical disorders, including hypertension, peripheral vascular disease, arteriosclerosis, and hypercholesterolemia.
The prior art document information related to the invention of this application includes the following (including documents cited at the international stage after the international filing date and documents cited when domestically transferred to another country).
(Prior art document)
(Patent document)
(Patent Document 1) International Publication No. 2018/0890909
(Patent Document 2) International Publication No. 2008/127813
(Patent Document 3) International Publication No. 02/43746
(Non-patent document)
(Non-Patent Document 1) ZHOU XIANG ET AL, "Ribosomal proteins: conjugations beyond the ribosome", JOURNAL OF MOLECULAR CELL BIOLOGY, Vol. 7, No. 2, April 2015 (2015-04), page 92-104
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862615223P | 2018-01-09 | 2018-01-09 | |
| US62/615,223 | 2018-01-09 | ||
| PCT/GB2019/050049 WO2019138219A1 (en) | 2018-01-09 | 2019-01-09 | Use of rps2 peptides for modulating endothelial cell dysfunction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021510157A JP2021510157A (en) | 2021-04-15 |
| JPWO2019138219A5 true JPWO2019138219A5 (en) | 2022-01-12 |
Family
ID=65036833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020537574A Pending JP2021510157A (en) | 2018-01-09 | 2019-01-09 | Use of RPS2 peptide to regulate endothelial cell dysfunction |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230210942A1 (en) |
| EP (1) | EP3737398A1 (en) |
| JP (1) | JP2021510157A (en) |
| KR (1) | KR20210013543A (en) |
| CN (1) | CN112423772A (en) |
| AU (1) | AU2019207951A1 (en) |
| BR (1) | BR112020013845A2 (en) |
| CA (1) | CA3087785A1 (en) |
| MX (1) | MX2020007336A (en) |
| WO (1) | WO2019138219A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018089909A1 (en) * | 2016-11-13 | 2018-05-17 | Imagine Pharma | Compositions and methods for treating diabetes, hypertension and hypercholesterolemia |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070042392A1 (en) * | 2000-02-03 | 2007-02-22 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
| CN101229363A (en) * | 2000-11-28 | 2008-07-30 | 蒙多生物技术许可股份公司 | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension |
| AUPR311601A0 (en) * | 2001-02-15 | 2001-03-08 | Adp Pharmaceutical Pty Limited | Matrix gene expression in chondrogenesis |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| AU2004293369A1 (en) * | 2003-03-03 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the treatment of systemic lupus erythematosis |
| GB0315248D0 (en) * | 2003-06-30 | 2003-08-06 | Hoffmann La Roche | HCV regulated protein expression |
| WO2008127813A1 (en) * | 2007-03-09 | 2008-10-23 | Hiberna Corporation | Hibernation-related genes and proteins, activators and inhibitors thereof and methods of use |
| US20150005183A1 (en) * | 2013-07-01 | 2015-01-01 | Expression Pathology, Inc. | Protein biomarkers of late stage breast cancer |
| WO2018089909A1 (en) | 2016-11-13 | 2018-05-17 | Imagine Pharma | Compositions and methods for treating diabetes, hypertension and hypercholesterolemia |
-
2019
- 2019-01-09 KR KR1020207022825A patent/KR20210013543A/en not_active Application Discontinuation
- 2019-01-09 CN CN201980007446.8A patent/CN112423772A/en active Pending
- 2019-01-09 US US16/960,505 patent/US20230210942A1/en not_active Abandoned
- 2019-01-09 BR BR112020013845-2A patent/BR112020013845A2/en not_active IP Right Cessation
- 2019-01-09 EP EP19700989.7A patent/EP3737398A1/en not_active Withdrawn
- 2019-01-09 WO PCT/GB2019/050049 patent/WO2019138219A1/en unknown
- 2019-01-09 CA CA3087785A patent/CA3087785A1/en active Pending
- 2019-01-09 AU AU2019207951A patent/AU2019207951A1/en not_active Abandoned
- 2019-01-09 JP JP2020537574A patent/JP2021510157A/en active Pending
- 2019-01-09 MX MX2020007336A patent/MX2020007336A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Okafor et al. | Allopurinol as a therapeutic option in cardiovascular disease | |
| Roy-Chaudhury et al. | Vascular access in hemodialysis: issues, management, and emerging concepts | |
| JP2009545310A5 (en) | ||
| Bongartz et al. | The nitric oxide donor molsidomine rescues cardiac function in rats with chronic kidney disease and cardiac dysfunction | |
| Boissiere et al. | Moderate exercise training does not worsen left ventricle remodeling and function in untreated severe hypertensive rats | |
| AU2003217815B2 (en) | Method of modulating inflammatory response | |
| JP2023033610A (en) | Methods for improving cardiovascular function and treating cardiovascular disease using recombinant ectonucleotide pyrophosphatase/phosphodiesterase (npp1) | |
| Aykut et al. | Pulsatile versus non-pulsatile flow to reduce cognitive decline after coronary artery bypass surgery: a randomized prospective clinical trial | |
| Miyamoto et al. | Zero mortality of continuous veno-venous hemodiafiltration with PMMA hemofilter after pediatric cardiac surgery | |
| Haque et al. | High mobility group box 1 levels in on and off-pump cardiac surgery patients | |
| Ji et al. | Evaluation by cardiac troponin I: the effect of ischemic preconditioning as an adjunct to intermittent blood cardioplegia on coronary artery bypass grafting | |
| JPWO2019138219A5 (en) | ||
| Qureshi et al. | Post-myocardial infarction complications during the COVID-19 pandemic–A case series | |
| Nemati et al. | Triple coronary artery bypass graft in a 10-year-old child with familial hypercholesterolemia | |
| Shin et al. | Unilateral pulmonary edema: a rare initial presentation of cardiogenic shock due to acute myocardial infarction | |
| Hammond et al. | The Plasma-Lyte 148 versus Saline (PLUS) study protocol amendment | |
| Akgul et al. | Levosimendan for weaning from cardiopulmonary bypass after coronary artery bypass grafting | |
| Venketasubramanian | Diagnosis and management of Takayasu arteritis | |
| Quennelle et al. | Dilatation of the aorta in children with advanced chronic kidney disease | |
| Durdu et al. | Promising utilization areas of therapeutic plasmapheresis in cardiovascular surgery practice | |
| Aggarwal et al. | Management of a Case of Aortic Valve Replacement with Left Ventricle Clot Removal Developing Acute Kidney Injury in Postoperative Period | |
| Jularic et al. | Takotsubo cardiomyopathy in complicated Pickering syndrome: endovascular therapy of an occluded renal artery | |
| Siddiqui et al. | Simultaneous allergic interstitial nephritis and cardiomyopathy in a patient on clozapine | |
| Cole | Pharmacology of nonsteroidal anti‐inflammatory drugs | |
| Paskalev et al. | TAMM HORSFALL PROTEIN: THE MEN BEHIND THE EPONYM |